Chisako Iriyama

Chisako Iriyama

Auto-generated profile, based on publicly available information

Chisako Iriyama

Department of Hematology, Fujita Health University School of Medicine , 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
KSKazuyuki Shimada
Kazuyuki Shimada
KYKenichi Yoshida
Kenichi Yoshida
YSYasuhiro Suzuki
Yasuhiro Suzuki
CIChisako Iriyama
Chisako Iriyama
YIYoshikage Inoue
Yoshikage Inoue
HKHitoshi Kiyoi
Hitoshi Kiyoi
Intravascular large B-cell lymphoma (IVLBCL) is a unique type of extranodal lymphoma characterized by selective growth of tumor cells in small vessels without lymphadenopathy. Greater understanding of the molecular pathogenesis of IVLBCL is hampered by the paucity of lymphoma cells in biopsy specimens, creating a limitation in obtaining sufficient tumor materials. To uncover the genetic landscape of IVLBCL, we performed whole-exome sequencing (WES) of 21 patients with IVLBCL using plasma-derived cell-free DNA (cfDNA) (n = 18), patient-derived xenograft tumors (n = 4), and tumor DNA from bone marrow (BM) mononuclear cells (n = 2). The concentration of cfDNA in IVLBCL was significantly higher than that in diffuse large B-cell lymphoma (DLBCL) (P < .0001) and healthy donors (P = .0053), allowing us to perform WES; most mutations detected in BM tumor DNA were successfully captured in cfDNA and xenograft. IVLBCL showed a high frequency of genetic lesions characteristic of activated B-cell–type DLBCL, with the former showing conspicuously higher frequencies (compared with nodal DLBCL) of mutations in MYD88 (57%), CD79B (67%), SETD1B (57%), and HLA-B (57%). We also found that 8 IVLBCL (38%) harbored rearrangements of programmed cell death 1 ligand 1 and 2 (PD-L1/PD-L2) involving the 3′ untranslated region; such rearrangements are implicated in immune evasion via PD-L1/PD-L2 overexpression. Our data demonstrate the utility of cfDNA and imply important roles for immune evasion in IVLBCL pathogenesis and PD-1/PD-L1/PD-L2 blockade in therapeutics for IVLBCL.

31 May 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
AOAkinao Okamoto
Akinao Okamoto
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
CIChisako Iriyama
Chisako Iriyama
NGNaoe Goto
Naoe Goto
HYHideyuki Yamamoto
Hideyuki Yamamoto
ATAkihiro Tomita
Akihiro Tomita

18 March 2025 in PNAS Nexus
Verified
Journal Article
Open access
CIChisako Iriyama
Chisako Iriyama
TITakaya Ichikawa
Takaya Ichikawa
TTTomokazu Tamura
Tomokazu Tamura
MTMutsumi Takahata
Mutsumi Takahata
TITakashi Ishio
Takashi Ishio
ATAkihiro Tomita
Akihiro Tomita
Patients with hematologic diseases have experienced coronavirus disease 2019 (COVID-19) with a prolonged, progressive course. Here, we present clinical, pathological, and virological analyses of three cases of prolonged COVID-19 among patients undergoing treatment for B-cell lymphoma. These patients had all been treated with anti-CD20 antibody and bendamustine. Despite various antiviral treatments, high severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) levels persisted for >4 weeks, and two of them succumbed to COVID-19. The autopsy showed bronchopneumonia, interstitial pneumonia, alveolar hemorrhage, and fibrosis. Overlapping cytomegalovirus, fungal and/or bacterial infections were also confirmed. Sequencing of SARS-CoV-2 showed accumulation of mutations and changes in variant allele frequencies over time. NSP12 mutations V792I and M794I appeared independently in two cases as COVID-19 progressed. In vitro drug susceptibility analysis and an animal experiment using recombinant SARS-CoV-2 demonstrated that each mutation, V792 and M794I, was independently responsible for remdesivir resistance and attenuated pathogenicity. E340A, E340D, and F342INS mutations in the spike protein were found in one case, which may account for the sotrovimab resistance. Analysis of autopsy specimens indicated heterogeneous distribution of these mutations. In summary, we demonstrated temporal and spatial diversity in SARS-CoV-2 that evolved resistance to various antiviral agents in malignant lymphoma patients under immunodeficient conditions caused by certain types of immunochemotherapies. Strategies may be necessary to prevent the acquisition of drug resistance and improve outcomes, such as the selection of appropriate treatment strategies for lymphoma considering patients’ immune status and the institution of early intensive antiviral therapy.

3 October 2026 in Blood Neoplasia
Verified
Journal Article
Open access
AOAkinao Okamoto
Akinao Okamoto
MSMasashi Sanada
Masashi Sanada
TYTakahiko Yasuda
Takahiko Yasuda
SKSeiichi Kato
Seiichi Kato
ASAkira Satou
Akira Satou
ATAkihiro Tomita
Akihiro Tomita